HLB Therapeutics Amends Meningococcal Vaccine Supply Contract to 4.0 Billion Won, Finalizing Performance Upon Contract Expiry

This amended disclosure reflects the finalized performance amounts after the expiry of the meningococcal vaccine supply contract signed on November 7, 2025.
The contract value decreased from approximately 6.49 billion won to 4.01 billion won, a reduction of 2.48 billion won, representing about 7.29% of recent annual sales.
Demand for the remaining volume has not disappeared, and there is potential for future recontracting or additional orders.
The counterparty is the Public Procurement Service, a highly credible government agency, and no special changes to contract terms have occurred.
No capital changes or shareholder dilution have occurred in connection with this contract.
[AI Summary]This amendment is a finalization of performance upon contract expiry; the reduction in contract value is a one-off factor and remaining demand remains valid. The transaction with the credible government counterparty carries low execution risk but may negatively impact short-term revenue.